MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

VTRS · NASDAQ-GS

Viatris Inc.

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$17.86As of Jul 28, 2026
Market capitalization$20.8B
52-week range$8.63–$17.75
S&P 500 portfolio weight0.03%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$12.00-32.8% vs. reference
Average$17.86+0.0% vs. reference
High$23.00+28.8% vs. reference
3 Buy3 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 6, 2026Jun 2026
Consensus EPS$0.624 estimates
Expected range$0.61–$0.62Low to high EPS
Dec 2026$2.46Street EPS consensus
Dec 2027$2.67Street EPS consensus
Dec 2028$2.86Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue-3.0% YoY$14.3B$14.74B
Operating income($2.66B)$0.01B
Net income($3.51B)($0.63B)
Operating cash flow$2.32B$2.3B
Capital expenditures($0.38B)($0.33B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

BNK Invest

Noteworthy ETF Inflows: IHE, VTRS, RPRX, ZTS

Zacks

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Zacks

VTRS or DHR: Which Is the Better Value Stock Right Now?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.